Last Update 31 Mar 26

Fair value Decreased 3.29%

VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside

Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions.

Analyst Commentary

Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results. Analysts are reassessing how current revenue trends, profitability, and P/E assumptions line up with the existing share price.

Bullish Takeaways

Bullish analysts see the updated price targets as a recalibration rather than a fundamental shift in thesis, aiming to keep valuation work in line with current revenue and margin assumptions.
Some view the refreshed models following Q4 results as a cleaner base for tracking execution, which can make it easier to judge whether Veracyte is meeting or beating their revised expectations.
The continued use of P/E based frameworks signals that analysts still view Veracyte through an earnings driven lens, which can be helpful for investors who prioritize profitability metrics alongside growth.
Supportive commentary ties the lowered targets to model updates, which suggests the changes are more about aligning numbers with recent information than a new, broad concern about the business model.

Bearish Takeaways

Bearish analysts highlight that the price target reductions, including the move to US$37 from US$48 with an Underweight rating, indicate concern that the prior valuation may have been too demanding relative to updated forecasts.
The Underweight stance signals caution on execution versus expectations, especially after reviewing Q4 results and adjusting revenue and margin forecasts accordingly.
Lowered targets suggest some analysts see a risk that current growth and profitability assumptions may not fully support earlier, higher valuation levels.
The clustering of downward revisions points to a more guarded outlook on how quickly Veracyte can translate its model into the earnings power that was previously embedded in higher P/E assumptions.

What's in the News

Veracyte reiterated 2026 total revenue guidance of 10% to 13% growth, or US$570 million to US$582 million, driven by testing revenue guidance of 14% to 16% growth, or US$560 million to US$570 million, excluding contribution from new tests (company guidance).
For the fourth quarter of 2025, Veracyte expects total revenue of US$138 million to US$140 million, described as an increase of 16% to 18% (company guidance).
For full year 2025, the company expects total revenue of US$515 million to US$517 million, described as an increase of approximately 16% (company guidance).
Veracyte also provided 2026 total revenue expectations of 10% to 13% growth, or US$570 million to US$582 million, in a separate guidance update, reinforcing the same revenue range for that year (company guidance).

Valuation Changes

Fair Value: trimmed from $48.60 to $47.00, a modest reduction in the central valuation estimate.
Discount Rate: effectively unchanged, shifting slightly from 7.07% to 7.06%.
Revenue Growth: lowered from 11.61% to 11.27%, indicating slightly more conservative revenue expectations in the model.
Net Profit Margin: nudged higher from 13.36% to 13.51%, reflecting a small uplift in projected profitability.
Future P/E: eased from 50.93x to 49.15x, implying a modestly lower valuation multiple applied to future earnings.

2 views

Key Takeaways

Expanding cancer diagnostics portfolio and clinical evidence are driving greater physician adoption, market penetration, and long-term top-line growth.
Operational efficiencies, AI integration, and strategic partnerships are enhancing technology differentiation, profitability, and competitive advantage.
Heavy dependence on core products and payer coverage, combined with industry shifts and mounting regulatory and reimbursement pressures, threatens Veracyte's growth, margins, and competitive positioning.

Catalysts

About Veracyte

Operates as a diagnostics company in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Broad and accelerating adoption of advanced genomic and noninvasive cancer diagnostics, combined with growing cancer incidence and aging populations, are steadily expanding the potential patient pool-directly supporting sustained double-digit volume and revenue growth across Veracyte's core product lines (notably Decipher and Afirma).
Pipeline momentum-with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months-positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.
Continued market penetration and share gains for Decipher Prostate, including expansion into metastatic and high-risk segments (now covering the entire prostate cancer spectrum), are fueling outsized growth; robust clinical evidence and guideline inclusions are likely to drive further physician adoption and payer coverage, bolstering both revenues and earnings visibility.
Investments in automation, next-generation sequencing platforms (e.g., NovaSeq X), and data analytics, combined with strategic restructuring (SAS sale), are driving operational efficiencies and lower cost of goods-translating into improving gross margins and higher long-term profitability.
Increasing clinical evidence, integration of AI/digital pathology, partnerships (Helix, biopharma), and a growing GRID/data platform are enhancing Veracyte's technology differentiation and providing leverage to value-based healthcare models; this strengthens the reimbursement outlook and competitive edge, supporting higher sustainable margins and earnings growth as volumes scale.

Veracyte Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Veracyte's revenue will grow by 11.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 12.8% today to 13.5% in 3 years time.
Analysts expect earnings to reach $96.2 million (and earnings per share of $1.09) by about March 2029, up from $66.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $110.8 million in earnings, and the most bearish expecting $85.5 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 49.7x on those 2029 earnings, up from 36.5x today. This future PE is greater than the current PE for the US Biotechs industry at 14.8x.
Analysts expect the number of shares outstanding to grow by 1.46% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.06%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heavy reliance on a limited number of core products-specifically Decipher and Afirma-exposes Veracyte to significant revenue concentration risk; any competitive disruption, reimbursement challenge, or technological obsolescence in these segments could materially impact overall revenue and earnings.
The long-term success of Veracyte's new product launches (e.g., Prosigna in the US, MRD platform) depends heavily on securing payer coverage, inclusion in key guidelines, and demonstrating sufficient clinical utility; delays or unfavorable outcomes in these areas could result in lower-than-expected revenue growth and margin pressure.
Increasing adoption of digital pathology and AI-driven analysis in diagnostics risks shifting competitive advantages toward larger, resource-rich companies or disruptors, potentially making it harder for Veracyte to maintain market share and superior margins.
Ongoing pricing and reimbursement pressures from laboratory benefit managers (LBMs), insurers, and healthcare systems-either through rate reductions, policy changes, or increased demands for clinical evidence-could put downward pressure on Veracyte's average selling prices (ASPs) and thus compress gross margins and future earnings.
Escalating regulatory scrutiny, especially related to diagnostics approvals, clinical evidence requirements, or European market IVDR (In Vitro Diagnostic Regulation) hurdles, may slow international rollout, increase compliance costs, and delay or reduce anticipated revenue expansion from geographic diversification.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $47.0 for Veracyte based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $53.0, and the most bearish reporting a price target of just $37.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $712.5 million, earnings will come to $96.2 million, and it would be trading on a PE ratio of 49.7x, assuming you use a discount rate of 7.1%.
Given the current share price of $30.44, the analyst price target of $47.0 is 35.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Veracyte?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion